Key result
In breast cancer patients exposed to anthracyclines and/or trastuzumab, modest, persistent LVEF declines were associated with sustained abnormalities in longitudinal strain and NT-proBNP.
Why the study?
Having recently identified three classes of LVEF change after anthracyclines and/or trastuzumab, the authors sought to characterize the clinical, biochemical, and functional profiles linked to these trajectory classes.
What are the clinical, biochemical, and functional profiles associated with distinct LVEF trajectories in breast cancer patients exposed to anthracyclines and/or trastuzumab?
Cohort (n=314)
What are the clinical, biochemical, and functional profiles associated with distinct LVEF trajectories in breast cancer patients exposed to anthracyclines and/or trastuzumab?
Answers are grounded in this paper and cite their sources.
Breast cancer patients with even modest, persistent LVEF declines after anthracycline or trastuzumab therapy exhibit sustained subclinical cardiac dysfunction and heart failure symptoms.
BACKGROUND: Breast cancer therapies are associated with a risk of cardiac dysfunction, most commonly defined by changes in left ventricular ejection fraction (LVEF). Recently, the authors identified 3 classes of LVEF change after exposure to anthracyclines and/or trastuzumab using latent class growth modeling. The objective of the current study was to characterize the clinical, biochemical, and functional profiles associated with LVEF trajectory class membership. METHODS: Transthoracic echocardiography and biomarker assessments were performed and questionnaires were administered at standardized intervals in a longitudinal cohort of 314 patients with breast cancer who were treated with anthracyclines and/or trastuzumab. Univariable and multivariable multinomial regression analyses evaluated associations between baseline variables and LVEF trajectory class membership. Generalized estimating equations were used to define mean changes in cardiovascular measures over time within each class. RESULTS: Among the 3 distinct subgroups of LVEF changes identified (stable [class 1]; modest, persistent decline [class 2]; and significant early decline followed by partial recovery [class 3]), higher baseline LVEF, radiotherapy, and sequential therapy with anthracyclines and/or trastuzumab were associated with class 2 or 3 membership. Sustained abnormalities in longitudinal strain and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were observed in patients in class 2, as were heart failure symptoms. Similar abnormalities were observed in patients in class 3, but there was a trend toward recovery, particularly for longitudinal strain. CONCLUSIONS: Patients with modest, persistent LVEF declines experienced sustained abnormalities in imaging and biochemical markers of cardiac function and heart failure symptoms. Further investigation is needed to characterize the long-term risk of heart failure, particularly in those with modest LVEF declines.
No takes yet. Share an insight, caveat, or question.
Demissei et al. (2019) conducted a cohort in Breast cancer (n=314). Anthracyclines and/or trastuzumab was evaluated on LVEF trajectory class membership and associated clinical, biochemical, and functional profiles. In breast cancer patients exposed to anthracyclines and/or trastuzumab, modest, persistent LVEF declines were associated with sustained abnormalities in longitudinal strain and NT-proBNP.
Synapse has enriched 10 related papers. Consider them for comparative context: